David Baker

David Baker, PhD, is a Nobel laureate and Professor of Biochemistry at the University of Washington School of Medicine. As Director of the Institute for Protein Design (IPD), he leads a team developing computational tools like Rosetta for protein engineering. His research spans protein design for medicine, sustainability, and technology, with notable achievements including AI-driven protein creation and antiviral nasal sprays. Baker holds adjunct roles in Genome Sciences, Bioengineering, Chemical Engineering, Computer Science, and Physics. He has published over 650 papers, secured 100+ patents, and co-founded 21 biotech firms. His awards include the 2024 Nobel Prize in Chemistry ("for computational protein design") and TIME’s 100 Most Influential People in Health (2024).

Educations:

• PhD in Biochemistry, University of California, Berkeley (advisor: Randy Schekman)
• Postdoctoral Research, UCSF Biophysics (advisor: David Agard)

Research Interests: Baker’s lab focuses on designing proteins to solve global challenges. Key areas include:

• Computational protein design for vaccines, antivirals, and industrial enzymes
• AI integration with biology to predict and engineer protein function
• Biomedical applications like logic-gate proteins for gene control
• Responsible innovation in AI-driven biotechnology

Recent Article Trends: Recent work emphasizes AI-enhanced protein design, pandemic response (e.g., SARS-CoV-2 antivirals), and synthetic biology tools for precision medicine. His lab’s innovations in nanoparticle vaccines and targeted cell therapies reflect a shift toward translational applications.

Awards & Recognition:

• 2024 Nobel Prize in Chemistry
• Breakthrough Prize in Life Sciences (2021)
• TIME Health Pioneer (2024)

Advising & Grants: Over 100 trainees have become faculty globally. Key grants include NIH, HHMI, and The Audacious Project. Technology transfer includes RosettaCommons licensing and 21+ companies (e.g., Arzeda, Icosavax).

Labs & Teams: Directs the IPD with core labs (Baker Lab, King Lab, etc.) focusing on protein design, vaccine development, and AI integration. Collaborates with institutions like MIT, Scripps, and Fred Hutch.